Microfluidic Concentrator for Polynucleotide Buffer Exchange
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies for manufacturing and formulating polynucleotide therapeutics, such as mRNA therapeutics, are prone to contamination and degradation, and centralized production is costly and inefficient, necessitating the development of scalable and point-of-care solutions that minimize touchpoints and ensure contamination reduction.
Innovation Solution
The use of microfluidic apparatuses and methods for concentrating and exchanging buffers in therapeutic polynucleotide solutions, employing single-pass tangential flow filtration with ultrafiltration membranes to separate biomolecules from solvents and enable buffer exchange, thereby improving stability and reducing contamination risks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If centralized production is used for polynucleotide therapeutics, then manufacturing scale is achieved, but contamination risk and degradation increase
Solution Approach 1:
The patent divides the manufacturing process into distributed microfluidic modules that can operate independently in controlled environments. Each microfluidic device performs specific functions (mixing, concentration, purification) in separate compartments, reducing cross-contamination risks while maintaining scalable production through modular replication.
Solution Approach 2:
The microfluidic apparatus operates in closed, controlled environments that maintain sterile conditions throughout the manufacturing process. The system uses sealed channels and integrated filtration to prevent contamination from external sources, creating an effectively inert environment for polynucleotide processing.
2Productivity
If conventional manufacturing processes are used, then production capacity is achieved, but touchpoints increase leading to higher contamination risk
Solution Approach 1:
The patent integrates multiple manufacturing functions (mixing, concentration, buffer exchange, purification) into a single microfluidic device. This consolidation reduces the number of transfer steps and touchpoints between different equipment, minimizing contamination opportunities while maintaining production capacity through continuous processing.
Solution Approach 2:
The microfluidic apparatus performs multiple functions within a single integrated system, including sample preparation, concentration, buffer exchange, and purification. This multi-functionality eliminates the need for separate equipment for each step, reducing touchpoints and simplifying the overall manufacturing process.
3Adaptability or versatility
If manual handling is used for therapeutic formulation, then flexibility is maintained, but contamination risk increases
Solution Approach 1:
The microfluidic system performs automated mixing, concentration, and buffer exchange operations without manual intervention. The device self-regulates flow rates, pressures, and timing through integrated control mechanisms, eliminating human contact with the therapeutic material while maintaining formulation flexibility through programmable parameters.
Solution Approach 2:
The patent replaces manual mechanical operations with automated microfluidic control systems. Electronic control replaces manual valve operation, and programmed flow control replaces manual mixing, thereby eliminating contamination risks associated with human handling while preserving formulation adaptability.
4Quantity of substance
If ultrafiltration membranes are used for concentration, then concentration factor increases, but membrane fouling may occur
Solution Approach 1:
The microfluidic system employs dynamic flow control to maintain optimal cross-flow velocities across the ultrafiltration membrane throughout the concentration process. By continuously adjusting flow rates based on concentration levels, the system prevents fouling while achieving high concentration factors, adapting operating conditions in real-time.
Solution Approach 2:
The patent implements continuous tangential flow filtration that maintains constant fluid motion across the membrane surface throughout the concentration process. This continuous action prevents particle accumulation and fouling, enabling sustained high-concentration operation without interruption for membrane cleaning or replacement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for high-concentration factors (up to 20-fold) and buffer exchange in a compact, aseptic environment, enhancing the stability and safety of therapeutic compositions for administration, while reducing contamination and enabling rapid, reproducible production of patient-specific therapeutics.
Implementation Method 1
employing single-pass tangential flow filtration with ultrafiltration membranes to separate biomolecules from solvents
Implementation Method 2
single-pass tangential flow filtration with ultrafiltration membranes to separate biomolecules from solvents
Data Source
AI summary
Microfluidic apparatuses including concentrators and buffer exchange regions that concentrate and exchange buffer. Also described are methods of passing a solution through a feed channel, filtering small molecules out of the feed channel by tangential flow filtration into a permeate channel adjacent to the first feed channel while maintaining a constant sheer rate relative to the membrane separating the feed channel from the permeate channel and exchanging buffer into the solution and concentrating the solution in a second region of the apparatus.